Overview

Bioavailability of ATI-1501 With Taste Test Sub Study

Status:
Completed
Trial end date:
2017-12-30
Target enrollment:
Participant gender:
Summary
Appili Therapeutics Inc. is developing an oral suspension formulation of metronidazole (ATI-1501), a taste-masked reformulation of metronidazole. The purpose of this study is to compare the relative bioavailability of ATI-1501 with the Reference Listed Drug (RLD) in healthy, adult volunteers to determine that it is Bioequivalent.
Phase:
Phase 1
Details
Lead Sponsor:
Appili Therapeutics Inc.
Collaborators:
INC Research
Syneos Health
Treatments:
Metronidazole